Sandoz/Momenta’s Copaxone Generic Clears FDA, But Court Action May Guide Launch Timing
This article was originally published in The Pink Sheet Daily
Executive Summary
Commercialization of the generic, which carries the brand name Glatopa, prior to a Federal Circuit ruling seems highly unlikely because it would be “at risk” and in the face of other rulings favoring Teva.